Artificial Intelligence (AI) has emerged as a transformative tool in predicting metastasis risk
and survival outcomes in cancer care. Traditional methods for assessing cancer progression …

In the absence of validated biomarkers, the management of low-volume prostate cancer as
defined by CHAARTED criteria may be guided by the timing of metastatic presentation. For …

Abstract Artificial Intelligence (AI) and Deep Learning have emerged as revolutionary tools
in the domain of cancer screening and risk assessment. Leveraging vast amounts of data …

Sodium Fluoride-18 production started in the 1940s and was described clinically for the first
time in 1962 as a bone-imaging agent. However, its use became dormant with the …

Background Castration-resistant prostate cancer (CRPC) is the severe and metastatic form
of prostate cancer and demands effective, reliable diagnostic and therapeutic approaches. It …

BACKGROUND. Breast cancer HER2 expression has been redefined using a three-tiered
system, with HER2-zero cancers considered ineligible for HER2-targeted therapy, HER2 …

Artificial intelligence (AI) has emerged as a transformative tool in healthcare, offering
innovative solutions to enhance patient quality of life (QoL). By leveraging machine learning …

Purpose To assess the diagnostic performance of various imaging modalities in detecting
and monitoring prostate cancer across different disease stages using diagnostic test …

Prostate cancer (PCa) is the second most diagnosed cancer and the sixth leading cause of
cancer death among men. 1 PCa is often suspected in the presence of elevated-serum …

Objectives To investigate the role of MRI measurements of peri-prostatic adipose tissue
(PPAT) in predicting bone metastasis (BM) in patients with newly diagnosed prostate cancer …